cobomarsen
single-stranded, chemically modified miR-155–targeting oligonucleotide
Networked: 3
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Beatty, Xuan:
2 articles
(01/2021 - 11/2018)
|
| 2. | Hermreck, Melanie:
2 articles
(01/2021 - 11/2018)
|
| 3. | Jackson, Aimee L:
2 articles
(01/2021 - 11/2018)
|
| 4. | Seto, Anita G:
2 articles
(01/2021 - 11/2018)
|
| 5. | Slack, Frank J:
2 articles
(01/2021 - 01/2020)
|
| 6. | Anastasiadou, Eleni:
1 article
(01/2021)
|
| 7. | Avigan, David:
1 article
(01/2021)
|
| 8. | Escolar, Diana M:
1 article
(01/2021)
|
| 9. | Gilles, Maud-Emmanuelle:
1 article
(01/2021)
|
| 10. | Marchese, Cinzia:
1 article
(01/2021)
|
Related Diseases
| 1. | Neoplasms (Cancer)
01/01/2021
- " Preclinical studies included the delivery of cobomarsen to highly miR-155-expressing ABC-DLBCL cell lines to assess any phenotypic changes, as well as intravenous injections of cobomarsen in NSG mice carrying ABC-DLBCL xenografts, to study tumor growth and pharmacodynamics of the compound over time. " 01/01/2021
- " Intravenous administration of cobomarsen in a xenograft NSG mouse model of ABC-DLBCL reduced tumor volume, triggered apoptosis, and derepressed direct miR-155 target genes. " 01/01/2021
- " Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo." 01/01/2020
- " Here, we review the role of miRNAs, and particularly miR-155, in cancers, and discuss progress on therapeutically targeting it, including the ongoing clinical trial of anti-miR-155 molecule Cobomarsen (MRG-106)."
|
| 2. | Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
|
| 3. | Lymphoma (Lymphomas)
|
|
Related Drugs and Biologics
Related Therapies and Procedures